Keywords: India, Complusory licensing, Roche, Herceptin, Bristol-Myers Squibb, Ixempra, Sprycel

Indian govt plans compulsory licences for trastuzumab, ixabepilone and dasatinib

Article | 15 January 2013

Print This

The Indian government's move to issue compulsory licences to three more patented cancer drugs has left a few of the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in